On August 29, a delegation led by Abdulla Azizov, First Deputy Minister of Health of Uzbekistan and Director of the Pharmaceutical Industry Development Agency, visited the Unicornshell Beijing Business Center. The delegation included Jakhongir Yakubov, Head of the Investment Department, and Azamat Abdinabiev, Assistant to the Director. The visit aimed to promote in‑depth exchanges and cooperation between the pharmaceutical industries of China and Uzbekistan, and to explore opportunities for industrial upgrading and technology implementation under the Belt and Road framework.

During the visit, the delegation focused on understanding Unicornshell's technological innovation in HPMC empty capsules, the achievements in the transformation of traditional Chinese medicine (TCM) modernization projects, and the expansion of international markets. In‑depth discussions were held on the need for pharmaceutical industry upgrading in Central Asia. The two sides explored cooperation paths for the export of HPMC pharmaceutical excipient technology and local production under the Belt and Road framework, opening new directions for pharmaceutical industry cooperation between China and Uzbekistan. The Uzbek side highly recognized Unicornshell's strengths in green pharmaceuticals, innovative materials, and intelligent manufacturing, and expressed anticipation for further deepening cooperation in the future.

Headquartered in Shanghai, Unicornshell focuses on the R&D, production, and sales of HPMC pharmaceutical excipients and innovative TCM formulations, striving to become a leader in the intelligent manufacturing of HPMC capsules. The company has successfully launched hypromellose (HPMC) capsules (first generation) and hydroxypropyl starch capsules (second generation), which are widely used in pharmaceuticals and nutraceuticals, providing green and safe excipient solutions for the global pharmaceutical industry. Relying on an industrial cluster model, Unicornshell promotes the deep integration of intelligent manufacturing and new materials, empowering the upgrading of traditional pharmaceutical industries with new productive forces, and supporting the development of green pharmaceuticals and TCM modernization.

Looking ahead, Unicornshell will take foreign trade channels as a breakthrough, focusing on expanding into Central Asia, Southeast Asia, and European markets. Through technology export and industrial synergy, the company will continue to advance its global layout and strive to become a leader in the HPMC capsule industry. This exchange not only deepened strategic mutual trust between China and Uzbekistan, but also set a new benchmark for international cooperation and technology promotion of HPMC pharmaceutical excipients, contributing "Chinese momentum" to the high‑quality development of the pharmaceutical industry in Belt and Road countries.